Lee:Literature PK/PD/PGx: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
No edit summary
Line 25: Line 25:


==PGx==
==PGx==
<biblio>
# Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther. 2009 Apr 21 PMID: 19383851
#1 pmid=18486526
# Strimpakos AS, Syrigos KN, Saif MW.  Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 2009 Jun;9(3):147-60. Epub 2009 Apr 21. Review.PMID: 19381163
#2 pmid=19147868
# Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. Review.PMID: 19203892
#3 pmid=18382463
# Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review.PMID: 19147868
#4 pmid=19022363
# McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review.PMID: 19139108
#5 pmid=18806753
# Burczynski ME. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy. Toxicol Lett. 2009 Apr 10;186(1):18-21. Epub 2008 Oct 31. Review.PMID: 19022363
#6 pmid=19383851
# Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008 Oct;7(10):807-17. Epub 2008 Sep 19. Review.PMID: 18806753
#7 pmid=19381163
# van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008 Jun;11(3):77-98. Epub 2008 May 19. Review.PMID: 18486526
#8 pmid=19203892
# Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov. 2008 Apr;7(4):293-305.PMID: 18382463
#9 pmid=19147868
#10 pmid=19139108
#11 pmid=
</biblio>

Revision as of 21:04, 19 January 2011

Home                  Research                  Lab Members                  Publications                  JC                      Links                  Internal                  Contact                 

Feel free to add articles ...

Classic PK/PD papers

  1. Csajka C and Verotta D. Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):227-79. DOI:10.1007/s10928-005-9002-0 | PubMed ID:16404503 | HubMed [1]
  2. Jusko WJ and Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 1994 Oct;56(4):406-19. DOI:10.1038/clpt.1994.155 | PubMed ID:7955802 | HubMed [2]
  3. Holford NH and Sheiner LB. Kinetics of pharmacologic response. Pharmacol Ther. 1982;16(2):143-66. DOI:10.1016/0163-7258(82)90051-1 | PubMed ID:6752972 | HubMed [3]
  4. Sharma A and Jusko WJ. Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 1998 Mar;45(3):229-39. DOI:10.1046/j.1365-2125.1998.00676.x | PubMed ID:9517366 | HubMed [4]
All Medline abstracts: PubMed | HubMed


PK/PD

  1. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, and Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci. 2008 Apr;29(4):186-91. DOI:10.1016/j.tips.2008.01.007 | PubMed ID:18353445 | HubMed [1]
  2. Mager DE and Jusko WJ. Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2008 Jun;83(6):909-12. DOI:10.1038/clpt.2008.52 | PubMed ID:18388873 | HubMed [2]
  3. Rajman I. PK/PD modelling and simulations: utility in drug development. Drug Discov Today. 2008 Apr;13(7-8):341-6. DOI:10.1016/j.drudis.2008.01.003 | PubMed ID:18405847 | HubMed [3]
  4. Mager DE, Wyska E, and Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos. 2003 May;31(5):510-8. DOI:10.1124/dmd.31.5.510 | PubMed ID:12695336 | HubMed [4]
All Medline abstracts: PubMed | HubMed

PGx

  1. Lurje G, Manegold PC, Ning Y, Pohl A, Zhang W, Lenz HJ. Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther. 2009 Apr 21 PMID: 19383851
  2. Strimpakos AS, Syrigos KN, Saif MW. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 2009 Jun;9(3):147-60. Epub 2009 Apr 21. Review.PMID: 19381163
  3. Bhushan S, McLeod H, Walko CM. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Clin Colorectal Cancer. 2009 Jan;8(1):15-21. Review.PMID: 19203892
  4. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb;59(1):42-55. Review.PMID: 19147868
  5. McWhinney SR, Goldberg RM, McLeod HL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009 Jan;8(1):10-6. Review.PMID: 19139108
  6. Burczynski ME. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy. Toxicol Lett. 2009 Apr 10;186(1):18-21. Epub 2008 Oct 31. Review.PMID: 19022363
  7. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov. 2008 Oct;7(10):807-17. Epub 2008 Sep 19. Review.PMID: 18806753
  8. van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resist Updat. 2008 Jun;11(3):77-98. Epub 2008 May 19. Review.PMID: 18486526
  9. Katz DA, Murray B, Bhathena A, Sahelijo L. Defining drug disposition determinants: a pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov. 2008 Apr;7(4):293-305.PMID: 18382463
Retrieved from "https://openwetware.org/mediawiki/index.php?title=Lee:Literature_PK/PD/PGx&oldid=486821"